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Comparative Analysis of Cognitive Function 
in Schizophrenia with and without   
Obsessive Compulsive Disorder 
 
 
 
ObjectiveaaWe investigated the neurocognitive deficits in schizophrenic patients with and 
without obsessive-compulsive disorder (OCD). 
MethodsaaWe grouped 27 patients as either obsessive-compulsive or non-obsessive-com-
pulsive based on the presence of OCD. The two groups completed the Yale-Brown Obses-
sive-Compulsive Scale (Y-BOCS), Positive and Negative Symptom Scale (PANSS), and 
Hamilton Depression Scale. The intelligence quotient (IQ) was tested using the Korean 
Wechsler Adult Intelligence Scale. The memory quotient (MQ) was tested using the Korean-
Auditory Verbal Learning and Korean-Complex Figure Test. The executive intelligence 
quotient (EIQ) was determined using the Kims executive intelligence test (EXIT). 
ResultsaaTen of the 27 patients had OCD. The compulsion score of Y-BOCS was positively 
correlated with positive symptoms, negative symptoms, and the total scores of PANSS. The 
OCD-schizophrenia patients had higher IQs. No difference was found in MQ. Although the 
EIQ did not differ between the two groups, the OCD-schizophrenia patients performed bet-
ter at the Stroop-interference and verbal fluency tests, which was highly dependent on ex-
ecutive function. 
ConclusionaaOur findings suggest that OCD may have a protective effect on some cog-
nitive function, at least in relatively early stage of illness. Moreover, based on clinical, neu-
rocognitive features, schizophrenia with OCD could be considered as a distinct subtype of 
schizophrenia.   Psychiatry  Invest  2009;6:286-293
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Introduction 
 
While there is general agreement that schizophrenia is heterogeneous in its clini-
cal presentation, there is also a widespread tendency to treat it as a single, unitary dis-
order. Additional non-schizophrenic psychopathologies in schizophrenia patients, such 
as depression, obsessive-compulsive disorder (OCD) and panic disorder are often ig-
nored. Hierarchical assumptions underlying this diagnostic system have largely kept
these syndromes hidden from view and hampered the study of their clinical validity.
1
However there has recently been renewed interest in comorbidity of schizophrenia and 
OCD, due to reports recognizing higher than expected comorbidity rates, the emerg-
ence or exacerbation of OCD after atypical antipsychotics,
2-5 and OCD as a predictor 
of poor prognosis.
6 
Schizophrenia and OCD share many similarities. Both are lifelong conditions with 
fluctuations in the severity of symptoms sharing a similar distribution for age at onset. 
The lifetime risks are about 1% for schizophrenia and 2-3% for OCD. Schizophre- 
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nia and OCD affect men and women equally.
7 Tibbo and 
Warneke
8 reported that both disorders share similar an-
atomical structures and parallel cortical-subcortical path-
ways, raising the possibility that a common functional ab-
erration can lead to the co-expression of seemingly dif-
ferent symptoms. 
Despite of these similarities, contemporary investiga-
tors contend that there may be a specific pattern of neu-
robiological dysfunction in patients afflicted with comor-
bid schizophrenia and OCD. However a number of qu-
estions must be answered to determine if this putative schi-
zo-obsessive subtype represents a true diagnostic entity: 
Did investigators accurately distinguish an obsession with 
poor insight from a delusion? Did individuals who exhi-
bit comorbid schizophrenia and OCD constitute a more 
severely psychotic patient population?   
Numerous methods allow the identification of schizo-
phrenia with OCD as a distinct type of schizophrenia. 
These methods include comparison of clinical features, 
neurophysiology and neuroimaging and neuropsycholo-
gical testing.
2,8-10 Among these methods, Berman
10 sug-
gested that cognitive impairments could be used to cor-
rectly classify the majority of schizophrenic patients into 
either an obsessive compulsive (OC) or non-obsessive 
compulsive (non-OC) group (over 80%). And in other re-
ports, varied results were obtained when tests of cogni-
tive functions were used to differential OC and non-OC 
schizophrenia; these tests included the Wisconsin Card 
Sorting Test (WCST), the Stroop Test, and the Trail Mak-
ing Test.
6,11 
In our study, the diagnosis of schizophrenia and OCD 
in subjects was determined by standardized interview in 
order to accurately differentiate obsession and delusion. 
We used neuropsychological tests to further examine the 
cognitive effects of OC symptoms in schizophrenia and 
we investigated whether patients with comorbid OCD and 
schizophrenia represent a special category of the schizo-
phrenic population. 
 
Methods 
 
Subjects 
After interviewing 87 individuals who were potentially 
suitable for this study, we recruited 27 participants whose 
diagnosis of schizophrenia was made according to the 
Diagnostic and Statistical Manual of Mental Disorder 
Fourth Edition-Text Revision (DSM-IV TR) diagnosis 
of schizophrenia.
12 Subjects originated from the outpati-
ent population at Inha University Hospital, Incheon, Korea, 
between February and June 2006. This study was approv-
ed by the institutional review board. Informed consent 
was obtained from all of the subjects after a careful ex-
planation of the purpose of the study and its procedure. 
The ages of participants ranged from 16 to 65 years. The 
participants had no history of severe head injury, organic 
brain disorder, substance use disorder, or severe medical 
illness. 
 
Methods 
Clinical and demographic measures included age, gen-
der, age of the onset of schizophrenia, duration of hospi-
talizations, length of schizophrenic illness, marital status, 
employment, and finished years of education. The diag-
nosis of OCD was determined by the Korean version of 
the Structured Clinical Interview for DSM-IV Axis I Dis-
order (SCID-IV) module pertaining to OCD, translated 
by Han and Hong.
13 We grouped the 27 patients as either 
OC or non-OC, and then used the Yale-Brown Obses-
sive-Compulsive Scale (Y-BOCS)14 to determine the se-
verity of OCD in the patients. The two groups completed 
the Positive and Negative Symptom Scale (PANSS),
15 
and the Hamilton Rating Scale of Depression (HRSD).
16 
If the patient was undergoing antipsychotic combination 
therapy, we transformed each antipsychotic dosage into 
its chlorpromazine equivalent dose and calculated the 
total dose.
17-20 
Each patient was interviewed by three investigators on 
the same day. To reduce inter-rater bias, we used a dou-
ble-blind method. The first investigator focused on cli-
nical and demographic variables and evaluated OCD se-
verity using Y-BOCS. The second investigator, who did 
not know the patient’s OCD status, assessed the patient’s 
clinical state using PANSS and HRSD. The third inves-
tigator, blind to the patient’s clinical state, administered 
a neurocognitive test. However, in the event that the pa-
tient’s psychiatric and cognitive evaluations could not be 
completed on the same day, the patient’s evaluations were 
completed as soon as possible, over a period not exceed-
ing 1 week. 
 
Neurocognitive test 
 
The Short Form of the Korean Wechsler Adult 
Intelligence Scale 
Due to time constraints, the intelligence quotient (IQ) 
was tested using the short form of the Korean Wechsler 
Adult Intelligence Scale (K-WAIS), which includes vo-
cabulary, math, picture arrangement, and block design.
21 
Each subtest covered verbal expression, concentration, 
problem solving, and visuospatial function.   
  
The Korean Auditory-Verbal Learning Test and 
Korean Complex-Figure Test
22 
The memory function test consisted of the Korean- 
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Auditory Verbal Learning Test (K-AVLT) and Korean-
Complex Figure Test (K-CFT). In K-AVLT, the exami-
ner presented 15 words repetitively 5 times and after 20 
minutes, checked delayed recall and delayed recognition. 
In the K-CFT procedure, the examiner presented a com-
plex figure. Each patient copied and drew the complex 
figure immediately; after 20 minutes, delayed recall was 
checked. The memory quotient (MQ) was obtained by ad-
ding up the score of verbal memory and visual memory; 
the mean is 100 and standard deviation is 15. In addition, 
each patient’s learning curve, memory retention and re-
trieval efficiency were calculated.   
 
Executive Intelligence Test   
To determine the executive intelligence quotient (EIQ), 
we used the Kims executive intelligence test (EXIT),
23 
which focuses on cognitive factors in executive function. 
Cognitive functions included concentration, vocabulary, 
visuospatial function, memory, and executive function. 
Since the executive function controls the others, we de-
termined EIQ by testing concentration, vocabulary, vi-
suospatial function, and memory. The following tests were 
used to assess cognitive functions: the Stroop test for con-
centration, verbal fluency for vocabulary, the Ruff figu-
ral fluency test for visuospatial function, and the K-AV-
LT for memory. The unique feature of EXIT is inclusion 
of qualitative and quantitative assessments in the tests. 
For example in the verbal fluency test, while the quanti-
tative score is calculated using the correct responses, the 
qualitative score is calculated with word repetition, vul-
gar word. The EIQ was calculated as the sum of the qu-
alitative score and quantitative score in EXIT; The mean 
is 100 and standard deviation is 15. In this study, we com-
pared the quantitative score and EIQ between the OC 
and non-OC groups. The Stroop test and K-AVLT includ-
ed subtests with high and low dependence on executive 
function. However, since the verbal fluency and Ruff fi-
gural fluency tests did not include subtests with low de-
pendence on executive function, we used the K-WAIS 
information and picture completion subtests. 
 
Data analysis 
The mean±standard deviation of patients’ age, onset 
age of schizophrenia, number of hospitalizations, finished 
years of education, chlorpromazine equivalent dose and 
duration of illness were analyzed using the independent 
t-test to compare OC and non-OC groups. Gender, mari-
tal status, and employment were analyzed using Fisher’s 
exact test . 
Scores obtained from PANSS and HRSD were anal-
yzed using the independent t-test. And scores for K-
WAIS, K-AVLT, K-CFT, and EXIT were also analyzed 
using the independent t-test with Bonferroni correction 
for multiple comparisons. The results from the Y-BOCS 
were analyzed using descriptive measure. Differences in 
cognitive function test scores between patients treated 
with antipsychotics only and patients receiving a combin-
ed treatment of antipsychotics and antidepressants were 
analyzed using the Mann-Whitney U test with Bonfer-
roni correction for multiple comparisons. 
Pearson’s correlation coefficients were calculated using 
scores from Y-BOCS, chlorpromazine equivalent dose, 
PANSS, K-WAIS, K-AVLT, K-CFT and EXIT. Further 
Pearson’s correlation coefficients were derived from the 
IQ, MQ, and EIQ scores. The analyses in this study were 
performed using the parametric method. However, gender, 
marital status, employment, and cognitive function test 
result variations between patients treated with antipsy-
chotics only and patients receiving a combined treatment 
of antipsychotics and antidepressants were analyzed us-
ing the non-parametric method, because of the small sam-
ple size.   
We used the Statistical Package for Social Science (SP-
SS; SPSS Inc, Chicago, IL, USA) 12.0 for Windows st-
atistical package, with a p value of 0.05 denoting signi-
ficance. 
 
Results 
 
Of the 27 patients we studied, 10 had OCD. The Y-BO-
CS scores for obsession were 6.10±5.02 and 7.90±5.72 
for compulsion, for a total of 14.00±6.34.  
The differences in between-group demographic vari-
ables and clinical rating scale scores were not significant 
except for the chlorpromazine equivalent dose (Table 1 
and 2). With regard to each patient’s main drug, 10 were 
on clozapine, 2 were on olanzapine, 5 were on aripipra-
zole, 1 was on quetiapine, 1 was on sertindole, 6 were on 
risperidone, 1 was on amisulpride, and 1 was on ziprasi-
done. There were three patients undergoing antipsycho-
tic combination therapy in the OC group and four in the 
non-OC group. Clozapine was the most common drug 
prescribed with 4 of 10 patients in OC group and 6 of 17 
patients in non-OC group. Anticholinergic drugs were 
prescribed for 2 patients in the OC group and 3 patients 
in the non-OC group. Seven patients in the OC group were 
treated with fluvoxamine (3 patients, 100-200 mg/day), 
fluoxetine (2 patients, 60 mg/day), or escitalopram (2 pa-
tients, 60 mg/day). 
As a result of the correlation between Y-BOCS and 
PANSS, the compulsion score of Y-BOCS was positively 
correlated with the positive symptoms score (p=0.006), 
the negative symptoms score (p=0.035), and the total 
score (p=0.009) of PANSS. The total score of Y-BOCS  
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was positively correlated with the positive symptoms 
score of PANSS (p=0.018)(Table 3). 
The K-WAIS test showed the IQ of patients with OCD 
to be average and significantly higher than that of non-
OCD patients, who had below-average IQs (OC group: 
105.10±14.32, non-OC group: 87.29±12.55, t=-3.29, p= 
0.003, significant after Bonferroni correction). The OC 
group also performed higher on the arithmetic subtest (OC 
group, 11.40±1.65; non-OC group, 8.12±3.08; t=-3.10, 
p=0.005, significant after Bonferroni correction), and block 
design subtest (OC group, 11.10±2.08; non-OC group, 
8.82±1.63; t=-3.17, p=0.004, significant after Bonferroni 
TABLE 3. Pearson’s correlation coefficient between Y-BOCS and other clinical rating scales
Y-BOCS 
 
Obsessive score  Compulsive score  Total score 
PANSS–positive symptoms  -0.015 0.790†  -0.726* 
PANSS–negative symptoms  -0.263  0.666*  -0.393 
PANSS–general psychopathology  -0.066 0.521  -0.418 
PANSS–total -0.146  0.771†  -0.581 
HRSD -0.276  0.030  -0.191 
Pearson’s correlation. *Correlation is significance at the 0.05 level (2-tailed), †Correlation is significance at the 0.01 level (2-tailed). Y-BOCS:
Yale-Brown Obsessive-Compulsive Scale, PANSS: Positive and Negative Symptom Scale, HRSD: Hamilton Rating Scale for Depression 
 
TABLE 4. Comparison of IQ and other subtest scores of K-WAIS between SPR patients with and without OCD 
SPR with OCD (N=10)  SPR without OCD (N=17)  Statistics 
Variable 
Mean±SD Mean±SD t  p-value 
IQ  105.10±14.32  87.29±12.55  -3.38  0.002* 
Vocabulary  011.60±3.06  09.35±2.06  -2.29  0.031 
Arithmetic  011.40±1.65  08.12±3.08  -3.10  0.005* 
Picture arrangement  009.60±2.95  08.82±2.27  -0.77  0.450 
Block design  011.10±2.08  08.82±1.63  -3.17  0.004* 
Independent t-test. *Significant level after Bonferroni correction: p=0.0125. IQ: intelligence quotient, K-WAIS: Korean Wechsler Adult 
Intelligence Scale, SPR: schizophrenia, OCD: obsessive-compulsive disorder   
TABLE 2. Comparison of clinical rating scale scores between SPR patients with and without OCD
SPR with OCD (N=10)  SPR without OCD (N=17)  Statistics 
Variable 
Mean±SD Mean±SD t  p-value 
PANSS-positive  13.40±3.710  12.41±3.970  -0.639  0.529 
PANSS-negative  06.80±6.370  15.53±5.410  -0.552  0.586 
PANSS-general psychopathology  31.20±8.090  28.94±6.590  -0.791  0.437 
PANSS-total  61.40±14.78  56.88±11.61  -0.883  0.386 
HRSD  05.60±4.220  04.47±3.450  -0.757  0.456 
Independent t-test. SPR: schizophrenia, OCD: obsessive-compulsive disorder, PANSS: Positive and Negative Syndrome Scale, HRSD: Ha-
milton Rating Scale of Depression 
 
TABLE 1. Comparison of demographic and clinical characteristics between SPR patients with and without OCD 
Variable SPR  with  OCD  (N=10) SPR    without  OCD  (N=17) Statistics  p-value 
Age (years)*  030.30±7.79  030.47±5.39 t=0.067  0.947 
SPR onset age (years)*  020.70±7.32  021.76±4.79 t=0.411  0.687 
Duration of hospitalization (years)*  002.60±2.07  002.53±1.87  t=0.093  0.927 
Illness duration (years)*  009.30±5.49  008.70±4.64 t=0.300  0.767 
Gender (F : M)†  3 : 7  7 : 10    0.692 
Marital status (unmarried or married)†  8 : 2  15 : 2    0.613 
Employment (employed : unemployed)†  2 : 8  2 : 15    0.613 
Finished years of education†  013.60±2.06  014.11±2.05  t=0.-630 0.534 
Chlorpromazine equivalent dose (mg)* 421.20±268.08 334.76±133.82   0.001‡ 
Data are presented as mean±standard deviation. *Independent t-test, †Fisher’s exact test, ‡p value is significance at the 0.05 level. SPR:
schizophrenia, OCD: obsessive-compulsive disorder 
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correction)(Table 4). 
On the memory test, the OC and non-OC groups both 
scored below average on MQ, with no significant differ-
ence between groups. The OC group performed higher 
on trial 1 (OC group, 11.40±1.42; non-OC group, 9.47± 
2.06; t=2.859, p=0.009, significant after Bonferroni cor-
rection), but the other memory subscale showed no sig-
nificant difference (Table 5).  
In EXIT, the OC group demonstrated below-average 
EIQ, whereas the non-OC group had a borderline EIQ 
level, but the groups did not differ significantly. In the 
EXIT vocabulary areas, the groups showed no signifi-
cant difference on the K-WAIS information test, which 
has a relatively low level of dependence on executive 
functioning. However, the OC group performed higher 
on the verbal fluency tests (OC group, 10.90±3.14; non-
OC group, 7.12±2.64; t=-3.350, p=0.003, significant after 
Bonferroni correction), which are highly dependent on 
executive functioning. The groups did not differ signifi-
cantly on the memory test, in which recognition had a 
low dependence and recall had a high dependence on ex-
ecutive function. The groups did not differ significantly 
on the concentration test, neither in the Stroop test-sim-
ple, which has a low dependence on executive function-
ing, nor the Stroop test-interference, which has a high 
dependence on executive functioning. Furthermore, the 
groups did not differ significantly on the visuospatial 
test. Of such tests, the Picture Completion test has a low 
dependence and the Ruff Figural Fluency test has a high 
dependence on executive functioning (Table 6).  
In the OCD group, to identify the effects of antidepres-
sants on cognitive functioning, we grouped 10 patients 
into either the antipsychotics-only group (3 patients) or 
the combined antipsychotics-and-antidepressants group 
TABLE 5. Comparison of MQ and other subtest scores of Rey-Kim between SPR patients with and without OCD 
SPR with OCD (N=10)  SPR without OCD (N=17)  Statistics 
Variable 
Mean±SD Mean±SD t  p-value 
MQ  85.60±7.20  83.24±13.83  -0.500  0.622 
Trial 1  11.40±1.42  09.47±2.06 2.859  0.009* 
Trial 2  09.60±2.01  07.52±2.64 2.291  0.031 
Trial 3  07.00±1.94  07.05±2.74 -0.065  0.949 
Trial 4  07.90±1.10  06.47±3.60 1.518  0.144 
Trial 5  08.30±2.40  06.94±3.28 1.233  0.230 
Delayed recall (auditory verbal)  06.80±2.90  07.41±3.18  0.498  0.623 
Delayed recognition (auditory verbal)  08.20±2.57  08.18±3.78  -0.017  0.986 
Learning curve  27.50±3.53  32.77±3.32  0.565  0.577 
Memory retention  26.17±32.62  46.35±32.04  1.570  0.129 
Retrieval efficiency  15.63±15.82  25.81±23.19  1.226  0.232 
Drawing  11.90±2.56  09.88±4.45  -1.494  0.148 
Immediate recall (visual)  07.90±3.35  06.88±3.76  -0.706  0.486 
Delayed recall (visual)  07.70±3.80  06.94±3.51  -0.526  0.603 
Independent t-test. *Significant level after Bonferroni correction: p=0.01. MQ: memory quotient, SPR: schizophrenia, OCD: obsessive-
compulsive disorder 
 
TABLE 6. Comparison of EIQ and subtest scores of EXIT between SPR patients with and without OCD
SPR with OCD (N=10)  SPR without OCD (N=17)  Statistics 
Variable 
Mean±SD Mean±SD t  p-value 
EIQ  87.80±20.98  78.76±15.49  -1.283  0.211 
Stroop test-simple  09.10±1.72  08.06±3.69  -0.991  0.332 
Stroop test-interference  11.40±2.54  08.12±3.62  -2.515  0.019 
Information* 10.10±0.74  09.06±2.02 -1.920  0.067 
Word fluency test  10.90±3.14  07.12±2.64  -3.350  0.003† 
Picture completion*  10.60±2.95  08.24±1.99 -2.690  0.012 
Ruff Figural Fluency test  07.50±4.52  06.76±3.73  -0.457  0.652 
K-AVLT Delayed recognition  08.20±2.57  08.18±3.78  -0.017  0.986 
K-AVLT Delayed recall  06.80±2.90  07.41±3.18  0.498  0.623 
Independent t-test. *Subtests of K-WAIS, †Significant level after Bonferroni correction: p=0.0083. EIQ: executive intelligence quotient, EXIT:
Executive Intelligence Test, SPR: schizophrenia, OCD: obsessive-compulsive disorder, K-AVLT: Korean-Auditory Verbal Learning Test 
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(7 patients). However, there were no significant difference 
between the groups with regard to IQ (p=0.908), MQ 
(p=0.819), or EIQ (p=1.000). Furthermore, there were no 
significant differences between the groups for any other 
subtests.  
Overall, there was no correlation between the chlor-
promazine equivalent dose and cognitive test. The obses-
sion score of Y-BOCS was negatively correlated with 
trial 2 (p=0.005), trial 4 (p=0.000), trial 5 (p=0.001), the 
delayed recall subtest (p=0.001) and the delayed recog-
nition subtest (p=0.003) in the memory subtest (Table 7). 
 
Discussion 
 
In this study, while the OC and non-OC groups did not 
appear to be different from a clinical perspective, we found 
a positive correlation between compulsion scores obtain-
ed with Y-BOCS and the positive symptoms score, the 
negative symptoms score, and the total score of PANSS. 
These findings do not support previous suggestions that 
obsession may arise from or be related to intrusive delu-
sion and that obsessions could be transformed into delu-
sions.
24 Our findings are compatible with those reported 
by Ongür and Goff.
11 They suggest that delusional indi-
viduals do more checking as a result of hypervigilance. 
And in our samples the obsessions were not correlated 
with positive symptoms and those patients with OCD did 
not have more positive symptoms than other patients, 
which suggests that the OCS are separate from symptoms 
of persistent psychosis in schizophrenia. 
The two groups we analyzed for cognitive function did 
not differ significantly either clinically or demographically. 
And although this result cannot be generalized, due to 
small sample size, antidepressant medications did not 
affect cognitive function. In our study, the OC group sh-
owed higher IQ measurements and had higher levels of 
concentration and visuospatial functioning. In contrast, 
some studies that have tested IQ using the Mini-Mental 
State Examination,
6 Wide Range Achievement Test, or 
WAIS information subtest did not find a significant dif-
ference in IQ between OC and non-OC groups.
10 This dif-
ference in results may have been due to the difference in 
TABLE 7. Pearson’s correlation coefficient between chlorpromazine equivalent dose, Y-BOCS and cognitive test 
Y-BOCS 
Cognitive test 
Chlorpromazine  
equivalent dose (mg)  Obsessive score  Compulsive score  Total score 
IQ  -0.002  -0.226  -0.004  -0.182 
Vocabulary  -0.048  -0.106  -0.066  -0.143 
Arithmetic  0.060  -0.075  -0.431  -0.330 
Picture arrangement  -0.178  -0.132  -0.108  -0.202 
Block design  -0.078  -0.382  -0.092  0.219 
MQ  0.280  -0.574  0.091  -0.372 
Trial 1  0.125  -0.192  0.331  0.147 
Trial 2  0.031  -0.810†  0.151  -0.505 
Trial 3  0.051  -0.524  0.220  -0.216 
Trial 4  0.231  -0.923†  0.263  -0.494 
Trial 5  0.180  -0.674*  0.527  -0.058 
Delayed recall (auditory verbal)  0.376  -0.877†  0.427  -0.308 
Delayed recognition (auditory verbal)  0.374  -0.827†  0.243  -0.436 
Drawing  0.195  -0.053  0.386  0.390 
Immediate recall (visual)  -0.019  -0.397  -0.412  -0.058 
Delayed recall (visual)  -0.174  -0.578  -0.328  0.161 
Learning curve  0.190  -0.612  0.302  -0.212 
Memory retention  0.276  -0.344  -0.071  -0.336 
Retrieval efficiency  0.092  -0.456  0.350  -0.045 
EIQ  -0.012  -0.288  0.170  -0.074 
Stroop test-simple  -0.039  -0.040  0.304  0.243 
Stroop test-intermediate  0.135  -0.500  0.381  -0.052 
Stroop test-interference  0.046  -0.040  0.140  0.158 
Word fluency test  0.155  -0.365  0.469  0.134 
Ruff Figural Fluency test  -0.239  -0.310  -0.212  0.054 
Pearson’s correlation. *Correlation is significance at the 0.05 level (2-tailed),  †Correlation is significance at the 0.01 level (2-tailed). Y-
BOCS: Yale-Brown Obsessive-Compulsive Scale, IQ: intelligence quotient, MQ: memory quotient, EIQ: executive intelligence quotient 
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test instruments. We used the short form of K-WAIS, 
which has been shown to be valid in Korea.
21 Additio-
nally, in this study, IQ was assessed in terms of concen-
tration, visuospatial function, vocabulary, and problem 
solving, all of which are under executive function con-
trol. Thus, in interpreting our results, the effect of each 
area itself must be distinguished from that of executive 
function. In our study, the total EIQ of the OC group was 
similar to that of the non-OC group, but the OC group 
scored higher on those vocabulary area subtests having 
a high dependence on executive functioning. Moreover, 
the difference between the groups was significant. Al-
though subjects in this study had relatively higher IQs 
than generally found among schizophrenia patients, the 
higher IQs of the OC group could be partially explained 
by the effect of this higher executive functioning.   
In this study, the OC group scored higher in Trial 1 on 
the K-AVLT, but the groups did not differ in other mem-
ory subscales. This result is in contrast to reports that 
OCD patients have poor visuospatial memory
25 and that 
schizophrenia patients have poor verbal memory.
26 Alth-
ough we predicted that OC patients would have poor 
memory function due to their high chlorpromazine equi-
valent dose and frequent prescription of clozapine, we 
found no differences between the OC and non-OC groups. 
And MQ may not be low as we expected because this 
study recruited patients with relatively high IQs in both 
the OC and non-OC group. However, in contrast with the 
fact that IQ was associated with MQ (p=0.001), EIQ (p= 
0.001) and MQ was associated with EIQ (p=0.006) in 
the non-OC group, MQ was not associated with IQ (p= 
0.067), EIQ (p=0.064) except as it correlated with IQ 
and EIQ (p=0.001) in the OC group. It appears that high 
IQ or EIQ in the OC group does not affect these results. 
Based on this finding we propose that schizophrenia with 
OCD is a distinct type of schizophrenia rather than the 
alternative that schizophrenia and OCD independently 
coexist. As obsessions increase it is conceivable that they 
interfere with the registration process in memory caus-
ing deficits in subsequent recall and recognition. How-
ever it does not induce the difference between OC and 
non-OC schizophrenia in MQ.   
In our study, the total EIQ of the OC group was simi-
lar to that of the non-OC group, but the OC group scored 
significantly higher on subtests having a high depend-
ence on executive functioning. With respect to executive 
function, some studies have suggested that patients with 
OCD perform more poorly on the WCST.
6,10,27 However, 
Borkowska et al.
28 conducted frontal lobe neuropsycho-
logical tests on patients having schizophrenia with and 
without OCD (mean illness duration 7 years) and found 
that the OC group scored higher than the non-OC group. 
Some studies have suggested that patients with both 
schizophrenia and OCD are more impaired across seve-
ral neuropsychological domains than those with just one 
of these conditions and suffer a pathophysiological dou-
ble jeopardy,
29 whereas in this study, the OC group per-
formed higher on IQ measurements and the MQ, EIQ of 
the OC group was similar to that of the non-OC group. 
These results can be explained by the difference of test 
instrument. While the WCST, Trail Making test, and St-
roop test are usually used to test frontal lobe function, 
those instruments characterize only the quantitative as-
pects of frontal lobe function rather than the combined 
qualitative and quantitative aspects, and are sensitive to 
specific frontal lobe functions rather than the whole. For 
measurement of collective functioning of frontal lobe 
function, EXIT is the most appropriate tool. 
And Hwang and Opler
30 further characterized comor-
bid OCD and schizophrenia into several categories: OCD 
onset before schizophrenia onset, simultaneous onset of 
OCD and schizophrenia, and OCD onset during schizo-
phrenia. Therefore in cross sectional study, there is pos-
sibility that subjects are heterogeneous. 
Finally, we considered illness duration of subjects. Po-
yurovsky et al.
7 reported that an OC group scored signi-
ficantly lower than a non-OC group on the Scale for the 
Assessment of Positive Symptoms (SAPS) formal thought 
disorder subscale and the Scale for the Assessment of 
Negative Symptoms (SANS) flattened affect subscale. 
They concluded that OCD may have a protective effect 
on some schizophrenic symptoms, at least in the early 
stages of the disease. In addition, Borkowska et al.
28 con-
ducted frontal lobe neuropsychological tests on patients 
having schizophrenia with and without OCD (mean ill-
ness duration 7 years) and found that the OC group scored 
higher than the non-OC group. Comparing his results with 
those of Hwang et al.,
6 who assessed patients with a mean 
illness duration of 18 years, Borkowska et al.
28 sug-
gested that OC symptoms may have an alleviating effect 
in the early stage of schizophrenia but that during the 
chronic course of the disorder, untreated OC symptoms 
may further compound the deteriorating clinical picture 
of schizophrenia. Our findings highlight the possibility 
that OCD may have a protective effect on some cognitive 
function, at least in relatively early stage of illness. We 
have also showed that schizophrenia with OCD could be 
considered as a distinct category of schizophrenia as oppos-
ed to viewing the patient as having two separate disorders. 
However, illness duration, character of subjects and 
test instrument differences do not fully explain our re-
sults. We studied only patients who agreed to participate. 
Thus, subject bias must be considered, since more seve-
rely affected patients with both disorders might have been  
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less likely to participate. And this study was limited by 
the sample population of stable outpatients, who are not 
fully representative of patients with schizophrenia. Also, 
because a group consisting of 10 patients with schizoph-
renia and OCD could be too small for a useful statistical 
analysis and we used multiple measurements, it is pos-
sible this reflects a difference due to chance. Thus, in fu-
ture studies, a larger sample size will be required. Finally, 
as this was a cross-sectional study, we could not consi-
der cognitive function change or the etiology of impair-
ment of cognitive function. Despite these limitations, our 
findings highlight the possibility that OCD may have a 
protective effect on some schizophrenic symptoms, at 
least in relatively early stage of illness and that based on 
this clinical, neurocognitive feature, schizophrenia with 
OCD can be considered as a distinct subtype of schizo-
phrenia. Further studies will be required to fully clarify 
the significance of obsession and compulsions in schizo-
phrenia. 
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